1.) Bipolar 2 disorder, current episode depressed 2.) Borderline personality disorder Prescriptions
Reading File
Asking for Preferences
Finding Sources
Finding Sources
Searching PubMed
"bipolar II disorder" AND "depression" AND pharmacotherapy
Searching PubMed
"borderline personality disorder" AND pharmacotherapy
Reading File
Reading File
Finding Sources
Finding Sources
Reading File
Finding Sources
Reading File
Finding Sources
Finding Sources
I now have comprehensive information from the textbooks. Here is the full pharmacotherapy answer:
Pharmacotherapy: Bipolar II Disorder (Current Episode Depressed) + Borderline Personality Disorder
Important Framing Note
These two diagnoses frequently co-occur and share overlapping symptoms (emotional dysregulation, impulsivity, affective instability). The prescribing challenge is to choose agents that address both conditions simultaneously, avoid medications that destabilize mood (e.g., antidepressant monotherapy), and use the target-symptom approach for BPD rather than trying to treat the diagnosis as a whole.
1. Bipolar II Depression - Pharmacotherapy
Evidence for bipolar II depression specifically is limited; most data is extrapolated from bipolar I trials. The following hierarchy is based on Kaplan & Sadock's Comprehensive Textbook of Psychiatry and the Maudsley Prescribing Guidelines (15th ed.).
First-Line Options
| Drug | Class | Notes |
|---|---|---|
| Quetiapine (IR or XR) | Atypical antipsychotic | Best placebo-controlled evidence for bipolar II depression specifically; improvement seen as early as week 1. Appropriate first choice for drug-naive patients. |
| Lithium | Mood stabilizer | Recommended by most experts as monotherapy despite limited bipolar II-specific data |
| Lamotrigine | Anticonvulsant/mood stabilizer | Particularly useful in bipolar II; prevents depressive recurrence more than mania; lacks FDA approval for acute bipolar II depression but widely used |
| Lurasidone | Atypical antipsychotic | Approved for bipolar depression; effective as monotherapy or added to a mood stabilizer |
| Lumateperone | Atypical antipsychotic | Recent monotherapy trials show robust efficacy in bipolar II depression; newer option worth considering |
| Valproate (divalproex) | Anticonvulsant/mood stabilizer | Recommended by experts despite limited controlled data in bipolar II depression |
Second-Line / Adjunctive Options
- Adjunctive modern antidepressant (e.g., SSRI or SNRI added to a mood stabilizer): Acceptable in bipolar II depression, especially without mixed features or rapid cycling. The risk of antidepressant-induced switch to hypomania is lower in bipolar II than bipolar I (7-14% vs. 14-23%). An ISBD Task Force endorses this approach except in rapid cycling or mixed features.
- Pramipexole, modafinil, omega-3 fatty acids, N-acetyl cysteine: Can be considered as adjuncts in refractory cases.
- ECT: Effective for bipolar II depression; reserved for severe/refractory cases.
Per Kaplan & Sadock's Comprehensive Textbook of Psychiatry: antidepressant monotherapy is not recommended for most bipolar II patients despite some small studies suggesting efficacy.
2. Borderline Personality Disorder - Pharmacotherapy (Target-Symptom Approach)
Pharmacotherapy is not the primary treatment for BPD - psychotherapy (especially DBT) is the cornerstone. However, medications are useful for specific, distressing symptom domains. The following is based on the target-symptom table from Kaplan & Sadock's Synopsis, the Textbook of Family Medicine, and Goldman-Cecil Medicine.
By Target Symptom
| Symptom Domain | Recommended Agents | Avoid |
|---|---|---|
| Depression / dysphoria | SSRIs, SNRIs, MAOIs, aripiprazole, lurasidone, ziprasidone, quetiapine, divalproex sodium | TCAs (narrow therapeutic index, overdose risk) |
| Mood instability / emotional lability | Lithium, lamotrigine, valproate, low-dose olanzapine, aripiprazole, clozapine | TCAs, standard antidepressants (risk of mood switch) |
| Anger / impulsive aggression | SSRIs, lithium, anticonvulsants (valproate, lamotrigine, topiramate), low-dose antipsychotics (haloperidol, aripiprazole, olanzapine) | Benzodiazepines (disinhibition risk) |
| Anxiety (chronic cognitive) | Psychotherapy, SSRIs, SNRIs, low-dose aripiprazole or quetiapine | Benzodiazepines (risk of dependence and disinhibition) |
| Brief psychotic episodes | Short-term risperidone, olanzapine, typical antipsychotics for duration of psychosis | - |
| Suicidal behavior | Aripiprazole, flupenthixol decanoate, fluphenazine decanoate, olanzapine | - |
| Interpersonal/relational problems | Aripiprazole, olanzapine, divalproex, topiramate | - |
Per Kaplan & Sadock's Synopsis: "Antipsychotics may help control anger, hostility, and brief psychotic episodes. Antidepressants improve the depressed mood common in BPD. Benzodiazepines should be used with caution given misuse risk."
3. Combined Prescribing Strategy (Both Diagnoses Together)
Given the overlap of these two conditions, several agents address symptoms of both simultaneously:
Preferred agents that work across both diagnoses:
- Quetiapine - Treats bipolar II depression (best evidence) + BPD anxiety, depression, and psychotic-like symptoms. Strong option to anchor treatment.
- Aripiprazole - Excellent BPD evidence across multiple symptom domains (anger, mood instability, anxiety, depression, suicidality); also used in bipolar maintenance.
- Lamotrigine - Useful for bipolar II depressive prophylaxis + BPD anger/impulsivity. Well-tolerated, low metabolic burden.
- Valproate (divalproex) - Covers bipolar II depression and BPD mood instability, aggression, and interpersonal problems.
- Lurasidone - FDA-approved for bipolar depression; also effective for BPD depressive and anxiety features.
- SSRIs (e.g., sertraline, fluoxetine) - Adjunctive for depressive and anxiety symptoms in both conditions; pair with mood stabilizer to reduce switch risk in bipolar.
What to Avoid
- Benzodiazepines as standing medications: disinhibition risk and abuse potential are high in BPD; contraindicated in most cases
- Antidepressant monotherapy without a mood stabilizer: risk of hypomanic switch in bipolar II
- TCAs: overdose lethality concern in BPD given suicidal behavior
Recent Evidence Update
A 2026 network meta-analysis in Molecular Psychiatry (PMID 41667836) is the most current systematic review of pharmacological treatments in BPD. A 2025 systematic review in Psychopharmacology Bulletin (PMID 40630973) addresses second-generation antidepressant monotherapy for acute bipolar II depression specifically - findings are relevant if considering an SSRI/SNRI in this patient.
Disclaimer: This is a clinical education summary based on authoritative textbooks and peer-reviewed literature. All prescribing decisions should be made by a licensed clinician using individualized patient assessment, including a full medication history, suicide risk assessment, and consideration of DBT or other psychotherapy as the primary BPD treatment.
This is a shared conversation. Sign in to Orris to start your own chat.